Shionogi said on August 18 that it has sued the Japanese and German units of US drug giant Merck & Co., alleging that their anti-HIV medicine Isentress (raltegravir) infringes the company’s patents related to integrase inhibitors. Shionogi filed lawsuits with…
To read the full story
Related Article
- Shionogi Loses HIV Patent Battle against MSD
September 10, 2018
- Shionogi Says UK Court Finds Its HIV Drug Patent Invalid, Set to Challenge Ruling
November 29, 2016
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





